Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 48

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

562

HTML

4637

Tables (1-3)

188

Sum=5387

Publishing Process of This Article

Item

Count

Browse

1020

Download

913

Sum=1933

Dec 28, 2013 (publication date) through Nov 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 28, 2013; 19(48): 9377-9382
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9377

Table 1 Maternal characteristics of the control group and tenofovir disoproxil fumarate-treated group

Maternal characteristics	Control group (n= 24)	Treated group (n= 21)
Mean age (yr)	26.9 ± 2.9	28.2 ± 4.1
HBV DNA (IU/mL)	8.31 log	8.28 log
ALT levels (U/L )	52 (19-77)	56 (22-71)
Serum creatinine levels (mg/dL)	0.81 (0.6-1.0)	0.79 (0.6-0.98)
Compensated cirrhosis	0 (0%)	2 (10%)

HBV: Hepatitis B virus; ALT: Alanine aminotransferase.

Citation: Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, Gulsun S, Barcin T, Kalkanli S, Dal MS, Ayaz C. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013; 19(48): 9377-9382
URL: https://www.wjgnet.com/1007-9327/full/v19/i48/9377.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i48.9377